Trial reportDrug design, development and therapy2026
Dexmedetomidine May Reduce the Incidence of Acute Kidney Injury in Elderly Patients Undergoing Orthopedic Surgery: A Randomized, Double-Blind Clinical Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative interventions in preventing postoperative delirium following orthopaedic surgery in the elderly: a Bayesian network meta-analysis.Journal of orthopaedic translation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is a common complication in elderly patients undergoing orthopedic surgery, yet the renoprotective role of dexmedetomidine in this patient population remains unclear. This study aimed to evaluate the effect of dexmedetomidine on the incidence of AKI in elderly patients undergoing lower extremity orthopedic procedures. Methods: In this randomized, double-blind, placebo-controlled trial, 300 patients aged ≥ 65 scheduled for lower extremity orthopedic surgery were randomized to receive either dexmedetomidine (0.4 μg/kg infused for 10 minutes before induction, followed by 0.4 μg/kg/h until 30 minutes before skin closure) or normal saline (control). The primary outcome was the incidence of AKI within 48 hours postoperatively, based on AKI Network criteria. Secondary outcomes included serum cystatin C and estimated glomerular filtration rate on postoperative day (POD) 1, 2, and 3, in-hospital complications (postoperative nausea and vomiting, delirium, pneumonia, stroke), intensive care unit admission, length of hospital stay, and in-hospital mortality. Results: Of 295 patients who completed the study (62.7% female; mean age, 74 years), AKI occurred in 4.7% (7/149) of the dexmedetomidine group compared with 11.6% (17/146) of the control group (odds ratio = 0.37; 95% CI, 0.15 to 0.93; Conclusion: Dexmedetomidine administration was associated with a reduced incidence of AKI in elderly patients undergoing lower extremity orthopedic surgery. The renoprotective effects of dexmedetomidine in this patient population warrant validation in multicenter trials. Clinical Trial Registration: Chinese Clinical Trial Registry (ChiCTR2400088225).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.